<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768270</url>
  </required_header>
  <id_info>
    <org_study_id>CQGOG0201</org_study_id>
    <nct_id>NCT04768270</nct_id>
  </id_info>
  <brief_title>The Culture of Ovarian Cancer Organoids and Drug Screening</brief_title>
  <official_title>Drug Screening of Patient-derived Organoids From Ovarian Cancer Culture to Personalized Therapy,an Exploratory Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chongqing University Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing University Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The tumor organoids platform can provide the precise genetic information and phenotype, as&#xD;
      well as the heterogeneity of the tumor, thus provide information on drug sensitivity specific&#xD;
      to the patient.This is an exploratory research to see if organoids testing could help guide&#xD;
      precision treatment for ovarian cancer(OC) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tissue will be received from operative specimens( primary ovarian carcinoma) at time of&#xD;
      primary cytoreductive surgery.Ovarian cancer(OC) organoids will be then cultured. Organoids&#xD;
      will be validated with a combination of Next Generation Sequencing (NGS) analysis and&#xD;
      immunohistochemistry (TP53, PAX8 etc). After then, the patient-derived organoids cultured&#xD;
      from OC will be compared the sensitivity to standard regimens (chemotherapies and targeted&#xD;
      agents) recommendated by NCCN guidlines versus patients treated in clinical practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 20, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>5 years</time_frame>
    <description>Progression-free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>1 year</time_frame>
    <description>CR+PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>1 year</time_frame>
    <description>CR+PR+SD</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>It is an observation trial.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        ovarian cancer patients who accept primary cytoreductive surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ovarian cancer patients who will accept primary cytoreductive surgery, with&#xD;
             histopathological type: low/high grade serous carcinoma, clear cell carcinoma,&#xD;
             endometrioid carcinoma, mucinous carcinoma.&#xD;
&#xD;
          2. ECOG score 0~1,age 18~70 years old&#xD;
&#xD;
          3. Expected survival over 6 months&#xD;
&#xD;
          4. The serum or urine pregnancy test must be negative within 7 days before enrollment for&#xD;
             the women of childbearing age who should agree that contraception must be used during&#xD;
             the trial&#xD;
&#xD;
          5. CBC：Hb≥70g/L、WBC≥3.5×109/ L 、ANC≥1.5×109/L、PLT≥80×109/L；&#xD;
&#xD;
          6. Serum ALT≤2×UL, AST≤2×ULN；Serum creatinine≤1.5×ULN；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Activity or uncontrol severe infection&#xD;
&#xD;
          2. Liver cirrhosis, Decompensated liver disease&#xD;
&#xD;
          3. History of immune deficiency, including HIV positive or suffering from congenital&#xD;
             immunodeficiency disease&#xD;
&#xD;
          4. Chronic renal insufficiency or renal failure&#xD;
&#xD;
          5. Has combined with other malignant tumor which diagnosed within 5 years and/or needed&#xD;
             to be treated&#xD;
&#xD;
          6. Myocardial infarction, severe arrhythmia and NYHA (New York heart association)≥2 for&#xD;
             congestive heart failure&#xD;
&#xD;
          7. During the treatment for complications, the drugs which lead to serious liver and/or&#xD;
             kidney function impairment need to be used, such as tuberculosis&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Dongling Zou, M.D.</last_name>
    <phone>+8613657690699</phone>
    <email>cqzl_zdl@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chongqing Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongling Zou, M.D.</last_name>
      <phone>+8613657690699</phone>
      <email>cqzl_zdl@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 20, 2021</study_first_submitted>
  <study_first_submitted_qc>February 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>February 20, 2021</last_update_submitted>
  <last_update_submitted_qc>February 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing University Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Dongling Zou</investigator_full_name>
    <investigator_title>Director of Gynecologic Oncology Department</investigator_title>
  </responsible_party>
  <keyword>tumor organoids</keyword>
  <keyword>drug sensitivity</keyword>
  <keyword>precision treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

